pharmaceutical investing Menlo Therapeutics Announces Results from a Phase 2 Trial of Serlopitant for Pruritus Associated with Atopic Dermatitis
pharmaceutical investing Menlo Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results
AnaptysBio Announces Positive Top-Line Proof-of-Concept Data For ANB020 In Moderate-to-Severe Baseline
pharmaceutical investing Sienna Biopharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results
pharmaceutical investing Dermira’s Share Price Takes a Hit as Two Clinical Trials Failed to Meet Co-Primary Endpoints
Dermira Initiates Phase 2b Dose-Ranging Study Evaluating Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis
pharmaceutical investing Immune Pharmaceuticals Announces the launch of REMAIN ™ , an international Overall Survival study with Ceplene® and low dose Proleukin® in REmission MAINtenance in Acute Myeloid Leukemia
Revolve Receives Approval from the Alberta Utilities Commission for the 15.7 MW Bright Meadows Solar Project
Terra Clean Energy Corp. Announces Agreement to Earn 100% Interest in 75 Past Producing Uranium Claims on The San Rafael Swell, Utah, United States
Silver47 Announces Closing of $23 Million Brokered LIFE Financing, Including Full Exercise of the Over-Allotment Option
